These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 23909063)

  • 1. Active surveillance not only reduces morbidity, It saves lives.
    Klotz L
    Oncology (Williston Park); 2013 Jun; 27(6):522, 593. PubMed ID: 23909063
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of localised prostate cancer: inform patients about adverse effects.
    Prescrire Int; 2012 Oct; 21(131):247. PubMed ID: 23185851
    [No Abstract]   [Full Text] [Related]  

  • 3. Should we really consider Gleason 6 prostate cancer?
    Nickel JC; Speakman M
    BJU Int; 2012 Mar; 109(5):645-6. PubMed ID: 22193242
    [No Abstract]   [Full Text] [Related]  

  • 4. Active surveillance for prostate cancer: has the time finally come?
    Aragon-Ching JB
    J Clin Oncol; 2010 Jun; 28(16):e265-6; author reply e267. PubMed ID: 20406916
    [No Abstract]   [Full Text] [Related]  

  • 5. The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study.
    McKenney JK; Simko J; Bonham M; True LD; Troyer D; Hawley S; Newcomb LF; Fazli L; Kunju LP; Nicolas MM; Vakar-Lopez F; Zhang X; Carroll PR; Brooks JD;
    J Urol; 2011 Aug; 186(2):465-9. PubMed ID: 21679996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Watchful waiting and active surveillance: the current position.
    Adolfsson J
    BJU Int; 2008 Jul; 102(1):10-4. PubMed ID: 18422774
    [No Abstract]   [Full Text] [Related]  

  • 7. Active surveillance: the Canadian experience.
    Klotz L
    Curr Opin Urol; 2012 May; 22(3):222-30. PubMed ID: 22453335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active surveillance failure for prostate cancer: does the delay in treatment increase the risk of urinary incontinence?
    Radomski L; Gani J; Trottier G; Finelli A
    Can J Urol; 2012 Jun; 19(3):6287-92. PubMed ID: 22704315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.
    Albertson PC
    Eur Urol; 2009 Jun; 55(6):1331-2. PubMed ID: 19286304
    [No Abstract]   [Full Text] [Related]  

  • 10. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
    Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
    J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostatic cancer: the case for surveillance.
    Smith PH
    Turk J Pediatr; 1984; 26(1-4):267-72. PubMed ID: 6537079
    [No Abstract]   [Full Text] [Related]  

  • 12. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.
    Aus G
    Eur Urol; 2009 Jun; 55(6):1331. PubMed ID: 19286303
    [No Abstract]   [Full Text] [Related]  

  • 13. Contemporary grading for prostate cancer: implications for patient care.
    Brimo F; Montironi R; Egevad L; Erbersdobler A; Lin DW; Nelson JB; Rubin MA; van der Kwast T; Amin M; Epstein JI
    Eur Urol; 2013 May; 63(5):892-901. PubMed ID: 23092544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localised prostate cancer - current treatment options.
    Duchesne G
    Aust Fam Physician; 2011 Oct; 40(10):768-71. PubMed ID: 22003477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance.
    Satkunasivam R; Kulkarni GS; Zlotta AR; Kalnin R; Trachtenberg J; Fleshner NE; Hamilton RJ; Jewett MA; Finelli A
    J Urol; 2013 Jul; 190(1):91-5. PubMed ID: 23321581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active surveillance: pitfalls to consider.
    Ercole B; Parekh DJ
    Arch Esp Urol; 2011 Oct; 64(8):695-702. PubMed ID: 22052752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
    Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
    BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PR07 interim results: lymph node status -- the elephant in the room.
    Kirollos M
    Eur Urol; 2012 Sep; 62(3):568. PubMed ID: 22727997
    [No Abstract]   [Full Text] [Related]  

  • 20. Prostatic carcinoma. Treated at categorical center, 1960-1969.
    Murphy GP; Saroff J; Joiner J; Gaeta J
    N Y State J Med; 1975 Sep; 75(10):1663-9. PubMed ID: 1059888
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.